Table 4.

Summary of miRNAs modulated by antidepressant drugs in human samples

miRNAs	Samples/tissue	Antidepressant drug	Results	References
miR-16 miR-30 miR-34 miR-128 miR-132 miR-134 miR-182 miR-183 miR-185 miR-212	Serum	Different SSRI and SNRI (4 weeks of treatment)	In patients treated with SSRI, miR-16, miR-183, and miR-212 levels increased significantly after 4 weeks of antidepressant treatment	Lin et al. (2018)
miR-451a miR-34a-5p miR-221-3p	Serum	Paroxetine (8 weeks of treatment)	Depressed patients had lower serum miRNA-451a, and higher serum miRNA-34a-5p and miRNA-221-3p as compared to controls; miRNA-34a-5p and miRNA-221-3p decreased, whereas miRNA-451a increased after paroxetine treatment	Kuang et al. (2018)
miR-151a-3p miR-221/222	In silico study	SSRI (paroxetine)	miR-151a-3p, miR-221/222, and their respective target genes, CHL1 and ITGB3, are implicated in the response to SSRI	Oved et al. (2017)
miR-130b miR-26a/26b let-7f miR-770-5p miR-34c-5p	Human U87 glioblastoma cells	Escitalopram (24, 48, 72 h)	Significant increase in let-7f, after both 48 h and 72 h and of miR-26a after 48 h of treatment	Maffioletti et al. (2017)
miR-146a-5p miR-146b-5p miR-425-3p miR-24-3p	Blood cells	Duloxetine (8 weeks of treatment)	Differential expression of miR-146a-5p, miR-146b-5p, miR-425-3p, and miR-24-3p according to treatment response	Lopez et al. (2017)
miR-1202 miR-135a miR-16	Blood cells	Escitalopram or Desvenlafaxine or Duloxetine (8 weeks of treatment)	In two different cohorts, responders displayed lower baseline miR-1202 levels compared with non-responders; miR-1202 levels increased after 8 weeks of antidepressant treatment	Fiori et al. (2017)
miR-1202	Blood cells	Desvenlafaxine (8 weeks of treatment)	Changes in peripheral miR-1202 levels were associated with changes in brain regions associated with depression and antidepressant response	Lopez et al. (2017)
miR-572 miR-663a	Neuroblastoma cell lines	Fluoxetine (24 h)	Fluoxetine increased the expression of both miR-572 and miR-663a	Mundalil Vasu et al. (2016)
414 miRNAs	Blood cells and PBMC	Citalopram (8 weeks of treatment)	414 miRNAs modulated highly correlated set of genes (modules) which are associated with clinical improvements.	Belzeaux et al. (2016)
222 miRNAs	RNA from plasma	Escitalopram (12 weeks of treatment)	Of 222 miRNAs, 40 miRNAs were differently expressed after treatment; 23 significantly over-expressed and 17 down-regulated	Enatescu et al. (2016)
miR-124	PBMC	Different antidepressant drugs (8 weeks of treatment)	The expression level of miR-124 was significantly down-regulated after antidepressant drug treatment	He et al. (2016)
miR-355	Blood cells	Citalopram (4 weeks of treatment)	Citalopram up-regulated miR-335 expression and down-regulated GRM4 mRNA levels	Li et al. (2015)
miR-135	Blood cells	Escitalopram (12 weeks of treatment)	Trend for higher expression after CBT vs escitalopram	Issler et al. (2014)
miR-1202	Human Neural Progenitor cells (NPCs) and blood cells	Citalopram or Imipramine (24 h or 15 days for NPCs; 8 weeks of treatment for depressed subjects)	MiR-1202 was up-regulated in NPCs after acute treatment with both citalopram and imipramine. Moreover, remitter depressed patients showed an up-regulation of miR-1202 after citalopram treatment	Lopez et al. (2014)
miR-221 miR-222	Human Lymphoblastoid cell lines	Paroxetine (21 days of treatment)	Decreased expression of miR-221 and miR-222 after paroxetine treatment	Oved et al. (2013)
30 miRNAs	Blood cells	Escitalopram (12 weeks of treatment)	Identification of 30 miRNAs modulated by antidepressant treatment: 28 miRNAs were up-regulated, and 2 miRNAs were down-regulated	Bocchio-Chiavetto et al. (2013)
42 miRNAs	Human Lymphoblastoid cell lines	Paroxetine (3 days of treatment)	Of the 42 miRNAs, 19 had higher expression levels in the LCLs with high sensitivity to paroxetine	Oved et al. (2012)
miR-145 miR-20b	PBMC	Different antidepressant drugs (8 weeks of treatment)	Increased miRNAs levels during treatment only in responder patients	Belzeaux et al. (2012)